Uveal Melanoma, Angiogenesis and Immunotherapy, Is There Any Hope?
Florian Castet(Institut d'Investigació Biomédica de Bellvitge), Josep M. Piulats(Institut Català d'Ornitologia), A. Cuéllar(Institut d'Investigació Biomédica de Bellvitge), Oriol Casanovas(Institut Català d'Oncologia), Sandra García‐Mulero(Bellvitge University Hospital), Rebeca Sanz‐Pamplona(Fundacion Agencia Aragonesa para la Investigacion y el Desarrollo)
Cited by 72
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
|Cancer Cell|2009|2.3k
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
|Cancer Cell|2005|1.6k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
|Journal of Clinical Oncology|2020|676